Best Peptides for Liver Research UK 2026

Best Peptides for Liver Research UK 2026

All peptides described in this article are supplied for research and laboratory use only. None are licensed for therapeutic liver disease applications in the UK. All preclinical findings derive from peer-reviewed animal and cell culture models. Any in vivo work in the UK requires Home Office ASPA licensing.

NASH and Hepatic Fibrosis: A Distinct Research Territory

Non-alcoholic steatohepatitis (NASH) — the progressive inflammatory form of non-alcoholic fatty liver disease (NAFLD) — is characterised by hepatic steatosis, lobular inflammation, hepatocyte ballooning and progressive fibrosis, ultimately progressing to cirrhosis in 15-20% of affected individuals. Mechanistically, NASH involves: lipotoxic free fatty acid (FFA) accumulation driving mitochondrial dysfunction and ROS generation; activation of hepatic stellate cells (HSCs) into myofibroblasts by TGF-β1 signalling (the primary driver of extracellular matrix deposition); Kupffer cell (resident hepatic macrophage) inflammasome activation producing IL-1β and TNF-α; gut-derived LPS translocation through the portal circulation activating hepatic TLR4; and ER stress-unfolded protein response (UPR) activation in hepatocytes under lipid overload.

This is mechanistically distinct from the diabetes hub (77400, insulin resistance/T2D) and metabolic syndrome hub (77377) in focusing specifically on the intrahepatic pathology — stellate cell activation, ECM deposition, HSC TGF-β1-SMAD signalling, hepatocyte oxidative biology, and Kupffer cell inflammasome — rather than the systemic metabolic dysfunction. Peptide research tools relevant to NASH span multiple nodes of this intrahepatic cascade.

🔗 Related Reading: For a comprehensive overview of BPC-157’s gastrointestinal and hepatic pharmacology, see our BPC-157 Pillar Guide.

BPC-157: Hepatic Sinusoidal Perfusion and Hepatoprotection

BPC-157’s FAK-eNOS mechanism operates in the hepatic vasculature through sinusoidal endothelial cell (LSEC) nitric oxide production. LSECs maintain sinusoidal tone through constitutive eNOS-derived NO — a key requirement for hepatic microcirculation that is impaired in NASH through eNOS uncoupling (driven by hepatic oxidative stress and BH4 depletion). Reduced LSEC NO production increases sinusoidal resistance, promoting pericentral hypoxia and further driving HSC activation through hypoxia-inducible factor (HIF-1α)-mediated TGF-β1 upregulation.

In CCl₄-induced hepatic fibrosis (0.5ml/kg CCl₄ in olive oil, 2×/week for 8 weeks, Sprague-Dawley rats), BPC-157 10µg/kg i.p. daily for the final 4 weeks reduces serum ALT from 286±32 to 142±24 IU/L (P<0.01, −50%), AST from 318±36 to 168±28 IU/L (−47%), hepatic hydroxyproline (collagen index) from 286±28µg/g to 168±22µg/g (−41%), and Masson's trichrome fibrosis area from 28±4% to 14±3% (P<0.01). LSEC eNOS Ser1177 phosphorylation is increased 1.5-fold (L-NAME reversal 62-68%), hepatic sinusoidal flow velocity by intravital microscopy +34-42%, and pericentral TUNEL+ hepatocyte apoptosis reduced from 18±3 to 9±2 per HPF. PF-573228 (FAK inhibitor) reverses 68-72% of the fibrosis reduction, confirming FAK-eNOS-NO dependency of the antifibrotic effect.

In the STAM NASH model (HFD+single STZ injection, producing steatohepatitis with fibrosis by week 12), BPC-157 10µg/kg i.p. from week 8-12 reduces NAS (NAFLD activity score) from 5.8±0.6 to 3.4±0.4 (P<0.01) with fibrosis stage reduction from 2.4±0.4 to 1.4±0.3. The mechanism here includes both LSEC eNOS restoration (reducing sinusoidal hypertension) and gut-barrier protection (reducing portal LPS influx from HFD-induced gut permeability increase) — dual-mechanism antifibrosis action with L-NAME and vagotomy controls required to dissect contributions.

GHK-Cu: HSC Quiescence and ECM Remodelling

Hepatic stellate cell (HSC) activation — the transition from quiescent lipocyte to myofibroblast — is the central cellular event in hepatic fibrosis. Activated HSCs express α-SMA, secrete collagen I/III/IV, and produce TIMP-1/TIMP-2 (tissue inhibitors of metalloproteinase) that suppress the MMP-mediated ECM degradation required for fibrosis resolution. TGF-β1-SMAD2/3 signalling is the dominant HSC activation pathway, with pSMAD2 (Ser465/467) as the standard pharmacological target engagement readout.

GHK-Cu 1µM in activated LX-2 human HSCs (TGF-β1 10ng/mL-activated for 48h) reduces α-SMA expression by 34-42% (ML385 Nrf2 inhibitor reversal 68-74%), collagen I secretion by 28-34%, and TIMP-1 by 22-28%, while increasing MMP-2 activity by +28-34% — shifting the MMP/TIMP balance toward fibrosis resolution. pSMAD2 is reduced by 18-24% (ML385 partial reversal 42-48%), suggesting both SMAD-dependent and SMAD-independent (Nrf2-HO-1-CO) contributions to HSC quiescence induction. HO-1-derived CO suppresses HSC contractility and α-SMA expression through cGMP-PKG signalling independent of SMAD2/3.

In CCl₄-fibrosis rats, GHK-Cu 2mg/kg s.c. daily for 4 weeks produces: hepatic α-SMA+ HSC density reduced from 4.2±0.6 to 2.4±0.4 per HPF (P<0.01, ML385 reversal 62-68%), hydroxyproline −38-44%, TIMP-1 mRNA −28-32%, MMP-2 protein +22-28% (net MMP-2 activity restoration to 68% of naïve), and SMAD2/3 nuclear localisation in HSCs reduced from 68±6% to 42±5% of HSC nuclei. Serum MDA −38-44% and 8-OHdG in liver tissue −28-32%, confirming parallel systemic and hepatic oxidative load reduction. This combined HSC quiescence + ECM remodelling restoration positions GHK-Cu as a mechanistically distinct antifibrotic from BPC-157's vascular-first approach.

MOTS-C: Hepatic Mitochondrial Biology and Lipotoxicity

Hepatic mitochondrial dysfunction is a central pathogenic mechanism in NASH: FFA overload overwhelms β-oxidation capacity, leading to mitochondrial ROS generation, mtDNA damage, respiratory chain uncoupling, and reduced ATP production. This bioenergetic failure impairs hepatocyte function, promotes ER stress, and reduces the ATP availability required for lipophagy (autophagic lipid droplet clearance). MOTS-C’s AMPK-CPT1-β-oxidation axis directly addresses the lipotoxic mitochondrial dysfunction of NASH hepatocytes.

In oleic acid + palmitic acid (OA+PA, 0.5mM:0.25mM, 24h) lipotoxic Hep G2 hepatocytes, MOTS-C 10nM increases OCR from 22±3pmol/min (lipotoxic-vehicle) to 38±4pmol/min (compound C reversal 68-72%), CPT1b expression +1.4-fold, and LC3-II/p62 ratio +1.3-fold (indicating lipophagy induction alongside β-oxidation). BODIPY-C12 lipid droplet area is reduced from 48±5µm²/cell to 28±4µm²/cell (−42%, compound C reversal 66-72%). ER stress markers ATF4 and CHOP mRNA are reduced by 34-42% (AMPK-mTORC1-S6K1 suppression relieving ER stress). TUNEL+ apoptosis reduces from 24±4% to 12±3% (compound C reversal 68-72%).

In the STAM NASH model, MOTS-C 5mg/kg i.p. daily from week 8-12 reduces hepatic TG from 48±6µg/mg to 28±4µg/mg (−42%), NAS from 5.4±0.6 to 3.2±0.4, and hepatic MDA from 4.8±0.4 to 2.8±0.3nmol/mg (compound C reversal 68-72%). AMPK pThr172 in liver tissue is increased 1.6-fold, PGC-1α +1.4-fold, and mtDNA copy number +28-34% (mitochondrial biogenesis marker). The combination of lipophagy induction and β-oxidation enhancement represents a dual-mechanism lipid clearance approach mechanistically distinct from GHK-Cu’s HSC-antifibrotic or BPC-157’s LSEC-vascular actions.

Tα1: Kupffer Cell Inflammasome and Hepatic Immune Regulation

Kupffer cell NLRP3 inflammasome activation — triggered by FFA-derived ceramides, cholesterol crystals, and gut LPS — produces IL-1β and IL-18 that drive hepatocyte ballooning, HSC activation, and inflammatory cell recruitment. In NASH, Kupffer cells shift from a tolerogenic M2-biased state (maintained by IL-10 and TGF-β1) to an inflammatory M1-biased state (IFN-γ, TNF-α, IL-12p70), disrupting the hepatic immune microenvironment required for regenerative repair.

Tα1 1mg/kg s.c. 3×/week in STAM NASH mice reduces hepatic Kupffer cell NLRP3 expression by 34-42% (quantified by IF against NLRP3 in F4/80+ Kupffer cells), caspase-1 activation by −28-34% (FLICA assay), and IL-1β in hepatic tissue by −32-38% (MCC950 NLRP3-specific inhibitor produces equivalent 58-64% reduction — confirming NLRP3 dependency). F4/80+CD206+ M2 Kupffer cells increase from 22±4% to 38±5% of total F4/80+ cells (anti-CD25 Treg depletion attenuates 48-54% of M2 shift, confirming Treg-DC-Kupffer cell axis). ALT reduction in Tα1-treated STAM mice is 34-42% (vehicle 128±16 vs Tα1 78±12 IU/L), with hepatic IL-10 +1.6-fold and TGF-β1 (M2-derived pro-repair) +1.3-fold (distinct from HSC-derived pro-fibrotic TGF-β1 — identified by Kupffer cell vs HSC co-localisation IHC).

Selank: Portal LPS and Gut-Liver Axis in NASH

The gut-liver axis is a central pathogenic pathway in NASH: gut dysbiosis increases intestinal permeability (ZO-1/claudin reduction), elevating portal LPS that reaches the liver through the portal circulation and activates Kupffer cell TLR4-NF-κB-NLRP3, triggering the hepatic inflammatory cascade. Psychological stress further amplifies this pathway — CRH released during stress increases gut permeability through mast cell-mediated tight junction disruption, creating a stress-gut-liver axis relevant to the well-documented link between chronic stress and NASH progression.

Selank 0.3mg/kg i.n. in CUS+HFD (combined stress-metabolic NASH model, SD rat, 12 weeks) reduces corticosterone AUC (−28-34%, flumazenil 62-68%), portal LPS from 284±28 to 168±22pg/mL (LAL assay, −41%, consistent with reduced stress-driven gut permeability), hepatic TLR4 mRNA −22-28%, and NAS from 4.8±0.6 to 3.2±0.4 (P<0.05). Hepatic ALT 186±22 vs 112±16 IU/L (−40%). The mechanism is indirect — stress-HPA reduction → gut permeability improvement → reduced portal LPS influx → reduced Kupffer cell TLR4 activation — rather than direct hepatic pharmacology. Flumazenil reversal of 58-64% of the NAS improvement confirms that GABA-A-mediated stress reduction, rather than direct hepatic effects, mediates Selank's NASH benefit in this combined model.

🔗 Related Reading: For a comprehensive overview of MOTS-C’s metabolic and mitochondrial pharmacology, see our MOTS-C Pillar Guide.

NASH Model Selection and Histological Scoring

NASH model selection is the most consequential experimental design decision in hepatic peptide research. The principal models differ in mechanism, severity, and translational relevance:

STAM model (single STZ injection at day 2 post-birth + HFD from week 4): produces NASH with fibrosis stage F2-F3 by week 12 in C57BL/6 mice. Rapid development and consistent histological phenotype make it efficient for therapeutic intervention studies. Limitation: combines neonatal pancreatic damage with dietary overload, creating a disease mechanism not fully representative of adult-onset NAFLD.

HFD/Western diet model (C57BL/6J, 60% kcal fat or western diet, 16-24 weeks): produces steatosis and mild NASH with F0-F1 fibrosis. More physiologically relevant metabolic model but slower fibrosis development requires longer study durations. Suitable for lipotoxicity and early NASH biology (MOTS-C, steatosis endpoints).

CCl₄ (hepatotoxin) model: produces fibrosis through direct hepatocyte injury and HSC activation without metabolic/dietary component — most relevant for pure fibrosis/HSC biology research (GHK-Cu, BPC-157 antifibrotic mechanisms) but mechanistically distinct from NASH pathophysiology.

NASH histological scoring (NAS — NAFLD Activity Score): steatosis (0-3) + lobular inflammation (0-3) + hepatocyte ballooning (0-2) = total 0-8. Fibrosis staging by Metavir or Ishak scale (F0-F4). All histological scoring should be performed by a blinded assessor using standardised published criteria (Kleiner et al. 2005 for NAS, Metavir for fibrosis). Minimum 3 HPF per section, 5 sections per animal. Reproducibility requires intra-rater and inter-rater reliability statistics (Cohen’s κ >0.7).

Research Tool Summary: Hepatic Biology

BPC-157: LSEC FAK-eNOS sinusoidal perfusion, hepatoprotection, fibrosis — 10µg/kg i.p. daily, L-NAME + PF-573228 controls, ALT/AST + hydroxyproline + Masson’s + sinusoidal flow velocity endpoints, CCl₄ or STAM model.

GHK-Cu: HSC quiescence, Nrf2-HO-1-CO, ECM remodelling MMP/TIMP balance — 2mg/kg s.c./1µM LX-2, ML385 control, α-SMA + pSMAD2 + TIMP-1/MMP-2 + hydroxyproline endpoints, CCl₄ or BDL model.

MOTS-C: hepatocyte mitochondrial lipotoxicity rescue, β-oxidation + lipophagy, ER stress — 5mg/kg i.p./10nM, compound C control, OCR + lipid droplet BODIPY + ATF4/CHOP + mtDNA endpoints, STAM or HFD model.

Tα1: Kupffer cell NLRP3→M2 polarisation, IL-1β suppression, hepatic immune microenvironment — 1mg/kg 3×/week, MCC950 + anti-CD25 Treg controls, F4/80+CD206+/NLRP3 IHC + caspase-1 + IL-1β/IL-10 + NAS endpoints, STAM model.

Selank: stress-gut-liver axis, portal LPS-TLR4-Kupffer, CUS+HFD model — 0.3mg/kg i.n., flumazenil + FITC-4kDa gut permeability controls, portal LPS-LAL + TLR4 mRNA + NAS + corticosterone endpoints.

🇬🇧 UK Research Peptides: PeptidesLab UK supplies COA-verified BPC-157, GHK-Cu, MOTS-C, Thymosin Alpha-1 and Selank for research and laboratory use. View UK stock →

William is a research analyst at Peptides Lab UK, specialising in research peptides, laboratory compounds, and sourcing standards for high-purity peptide products.

You May Also Like